The Motley Fool

Why Amaysim, Medical Developments, Treasury Wine, & Volpara stormed higher

It has been a positive day of trade for the S&P/ASX 200 index on Tuesday. At the time of writing the benchmark index is up 0.25% to 6,670.4 points.

Four shares that are climbing more than most today are listed below. Here’s why they are storming higher:

The Amaysim Australia Ltd (ASX: AYS) share price has rocketed 15% higher to 39 cents. Investors have been buying the telco company’s shares after its revealed changes to its non-director key management personnel remuneration structure. Management believes these changes more directly align remuneration with shareholder interests over the longer term. These changes will see certain personnel rewarded for underlying EBITDA and mobile subscriber growth.

The Medical Developments International Ltd (ASX: MVP) share price has surged 9.5% higher to $5.66. This morning the healthcare company provided an update on its Penthrox product. That update revealed that data across 11 abstracts of studies conducted throughout Europe have demonstrated multiple positive results for Penthrox. This includes Penthrox demonstrating superiority over intravenous morphine, paracetamol, ketoprofen, and NSAIDS within a trauma setting.

The Treasury Wine Estates Ltd (ASX: TWE) share price has rebounded with a 3.5% gain to $16.98. The wine company’s shares fell heavily on Monday after it announced that CEO Michael Clarke will retire in 12 months. One broker that sees this share price weakness as a buying opportunity is UBS. It doesn’t believe investors should be concerned and continues to rate its shares as a buy with a $20.50 price target.

The Volpara Health Technologies Ltd (ASX: VHT) share price has risen 3.5% to $1.68. This morning the healthcare technology company released its latest quarterly update. Volpara reported annualised recurring revenue (ARR) including the MRS acquisition of NZ$15.7 million (US$10.3m) for the September quarter. It also advised that it is now selling its software to assist in the detection of both breast and lung cancer.

5 stocks under $5

We hear it over and over from investors, "I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I'd be sitting on a gold mine!" And it's true.

And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

*Extreme Opportunities returns as of June 5th 2020

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited and VOLPARA FPO NZ. The Motley Fool Australia owns shares of and has recommended Treasury Wine Estates Limited. The Motley Fool Australia has recommended Medical Developments International Limited and VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Related Articles...